CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo

Corporate Breaking News

Home : CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo

Dec 07 2021	CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2021 /PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), today announced the presentation of preclinical data suggesting that the Company's chemogenetic gene therapy platform can control focal seizures in vivo. Collectively, the results showed...


Source:https://www.prnewswire.com:443/news-releases/coda-biotherapeutics-chemogenetic-gene-therapy-platform-can-control-focal-seizures-in-vivo-301438518.html

Related News
» Court Approves Entry into Exit Financing Commitment Letters and Sets Date for Confirmation Plan Hearing » IHG Hotels & Resorts and Coca-Cola unveil "Santa's Suite Retreat" in countdown to Christmas